Durable complete radiographic and biochemical response to olaparib in BRCA2-mutated metastatic castration-resistant prostate cancer: a long-term responder case | Synapse
March 3, 2026Open Access
Durable complete radiographic and biochemical response to olaparib in BRCA2-mutated metastatic castration-resistant prostate cancer: a long-term responder case
Key Points
Durable biochemical and radiographic responses were observed over an extended follow-up period.
Significant long-term effects of olaparib treatment were highlighted in a patient with BRCA2 mutation.
Observational analysis of a long-term responder reveals important insights into treatment efficacy.
Success in this case suggests potential for further exploration in similar metastatic cancer scenarios.